FHTXFoghorn Therapeutics Inc
About Foghorn Therapeutics Inc
Foghorn Therapeutics (NASDAQ:FHTX) harnesses its pioneering Gene Traffic Control™ platform to discover and develop innovative therapies targeting diseases with a genetic basis, particularly cancer. The company's mission is centered around unlocking the vast potential of the human genome to revolutionize treatment options for patients battling these serious conditions. Through a deep understanding of chromatin biology, Foghorn Therapeutics strives to lead the way in creating a new wave of precision medicine. Their projects range from early discovery to clinical development, emphasizing a commitment to bringing groundbreaking treatments from the lab bench to bedside.
What is FHTX known for?
Snapshot
Public US
Ownership
2015
Year founded
131
Employees
Massachusetts, United States
Head office
1 of 4
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...
Operations
All Locations
United States
Produtos e/ou serviços de Foghorn Therapeutics Inc
- FHD-286 for treatment of myeloid leukemia and solid tumors, aiming at enzymatic activity modulation of BRG1 and BRM, part of the chromatin remodeling complex.
- FHD-609, a targeted protein degradation approach focused on inhibiting BRD9, a component of the non-canonical BAF (ncBAF) complex, for treating synovial sarcoma and SMARCB1-null tumors.
- Gene Traffic Control platform, leveraging proprietary insights into the Chromatin Regulatory System to identify novel drug targets and understand disease mechanisms.
- Collaboration with multiple biopharmaceutical companies to use the Gene Traffic Control platform for discovering novel therapeutic targets in various diseases.
- Development of small molecule inhibitors targeting the chromatin remodeling complexes to treat cancers with specific genetic alterations.
- Investigation into the role of chromatin dysregulation in cancer to identify potential therapeutic targets and biomarkers for novel treatments.
equipe executiva do Foghorn Therapeutics Inc
- Mr. Adrian H. B. GottschalkPresident, CEO & Director
- Dr. Anna Rivkin Ph.D.Chief Business Officer
- Dr. Gerald R. Crabtree M.d.Founder & Member of Scientific Advisory Board
- Mr. Jeffrey A. Sacher M.B.A.Interim CFO & Treasurer
- Dr. Steven F. Bellon Ph.D.Chief Scientific Officer
- Ms. Karin HellsvikChief of Staff to the CEO, VP of Corporate Affairs & Investor Relations
- Mr. Michael J. LaCascia J.D.Chief Legal Officer
- Mr. Saurabh Sewak Ph.D.Vice President of Corporate Development
- Mr. Carlos CostaChief People Officer
- Dr. Alfonso Quintas Cardama M.D.Chief Medical Officer